NEOFORDEX
LIVE

Serial Number

97052171

Owner

LABORATOIRES C.T.R.S.

Attorney

Pina Campagna

Filing Date

Sep 29, 2021

Add to watchlist:

No watchlists yet
View on USPTO

NEOFORDEX Trademark

Serial Number: 97052171 • Registration: 6888402

NEOFORDEX is a trademark filed by LABORATOIRES C.T.R.S. on September 29, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

LABORATOIRES C.T.R.S. (6 trademarks)

68 rue de l'Est

Entity Type: 99

Trademark Details

Filing Date

September 29, 2021

Registration Date

November 1, 2022

Published for Opposition

August 16, 2022

Goods & Services

Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, namely, amyloses, and purpura, namely, thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia. chemical preparations for medical and pharmaceutical use for treating haematological diseases, namely, amyloses, and purpura, especially thrombocytopenic purpura

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 1, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 1, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 12, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 5, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 5, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 5, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 27, 2021 NWOS
NEW APPLICATION ENTERED
Oct 2, 2021 NWAP